As Fennec Pharmaceuticals approaches its next earnings report, investors are eager to see if the company can maintain its momentum.
Fennec Pharmaceuticals Inc (FRX.TO) is set to report its earnings for the fiscal period ending June 30, 2026, on August 11, 2026, before the market opens. Investors are closely watching, especially given the company's recent performance and the anticipated EPS estimate of -$0.02. Historical trends have shown mixed results, making this upcoming report crucial for the biotech firm.
Recent earnings trend
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$556.49M
52W high
$16.10
52W low
$7.59
1W change
+15.67%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 484.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+484.1% Upside
Current Price
C$16.02
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
55.0%
Annualized
90-Day Vol
83.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$19.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$17.00 | C$14.06 – C$20.56 |
| 60 trading days | C$18.05 | C$13.80 – C$23.60 |
| 90 trading days | C$19.15 | C$13.79 – C$26.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 6 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-11 | — | 0.0200 | — |
| 2026-03-31 | 2026-05-14 | 0.0137 | -0.0200 | +168.5% |
| 2025-12-31 | 2026-03-24 | -0.1400 | 0.0500 | -380.0% |
| 2025-09-30 | 2025-11-13 | -0.0300 | -0.0400 | +25.0% |
| 2025-06-30 | 2025-08-14 | -0.1500 | -0.0400 | -275.0% |
| 2025-03-31 | 2025-05-13 | -0.0600 | -0.1200 | +50.0% |
Advertisement
Investor takeaway: Fennec's ability to meet or exceed EPS estimates will be key for investor sentiment, especially after two earnings beats in the last four quarters. The market will also focus on revenue growth, which is expected to rise significantly compared to last year.
89.8% EPS Growth Expected Year-Over-Year
Fennec's projected EPS growth of 89.8% compared to the same period last year highlights the company's potential for recovery and growth, despite current challenges.
Bull case
If Fennec Pharmaceuticals beats the consensus EPS estimate, it could boost investor confidence and drive the stock price closer to analyst targets, which suggest substantial upside.
Bear case
On the other hand, missing the EPS estimate could raise concerns about the company's growth trajectory, especially given the recent downward revisions in EPS expectations.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
